Compliance Rate

Compliance Rate 51.23%
Compliant submissions 187
Incompliant submissions 178
Total trials 365

My Organizations' Clinical Trials

Showing 825 of 2400 entries
View as:

Evaluating the Safety, Tolerability, and Effect of a Human Monoclonal Antibody (VRC01) on Markers of HIV Persistence in HIV-Infected Adults Receiving Antiretroviral Therapy (ART)

Phase: N/A Priority: Normal
NCT ID: NCT02411539 Org: User:
Start: 08/25/15 End: 09/29/16 Due: 09/29/17

Safety and Immunogenicity of an HIV Vaccine in Normal Adult Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT00083330 Org: User:
Start: 05/18/04 End: 10/01/09 Due: 10/01/10

Immune Responses to Mycobacterium Tuberculosis

Phase: N/A Priority: Normal
NCT ID: NCT00340990 Org: User:
Start: 10/06/03 End: 11/27/15 Due: 11/27/16

Comparison of Two Treatments to Prevent Invasive Fungal Infections in Patients Who Have Received Liver Transplants

Phase: N/A Priority: Normal
NCT ID: NCT00001107 Org: User:
Start: - End: 11/30/05 Due: 11/30/06

Surveillance of Streptococcal Infections in Children in India

Phase: N/A Priority: Normal
NCT ID: NCT00342199 Org: User:
Start: 07/03/01 End: 02/26/14 Due: 02/26/15

Metabolic Effects of Non-Thymidine Analogue Anti-HIV Medications

Phase: N/A Priority: Normal
NCT ID: NCT00433992 Org: User:
Start: 04/30/06 End: 12/31/09 Due: 12/31/10

Evaluating the Safety and Immune Response of an H7N7 Vaccine in Healthy Adults

Phase: N/A Priority: Normal
NCT ID: NCT01534468 Org: User:
Start: 03/31/12 End: 03/31/14 Due: 03/31/15

Impact of Antimalarial Treatment on Measures of T Cell Suppression/Regulation in Healthy Adults From Doneguebougou, Mali

Phase: N/A Priority: Normal
NCT ID: NCT02659566 Org: User:
Start: 01/15/16 End: 06/12/18 Due: 06/12/19

Effect of Concomitant Mansonella Perstans Microfilaremia on Immune Responses Following Single Dose Praziquantel in People With Schistosomiasis

Phase: N/A Priority: Normal
NCT ID: NCT02734186 Org: User:
Start: 04/06/16 End: 12/14/18 Due: 12/14/19

Modified Stem Cell Transplantation Procedure for Treating Chronic Granulomatous Disease

Phase: N/A Priority: Normal
NCT ID: NCT00006417 Org: User:
Start: 10/31/00 End: 11/30/04 Due: 11/30/05

pCCLCHIM-p47 (Lentiviral Vector Transduced CD34 Plus Cells) in Patients With p47 Autosomal Recessive Chronic Granulomatous Disease (AR-CGD)

Phase: N/A Priority: Normal
NCT ID: NCT06253507 Org: User:
Start: 06/25/24 End: 03/31/27 Due: 03/31/28

Ebola and Marburg Virus Vaccines

Phase: N/A Priority: Normal
NCT ID: NCT00605514 Org: User:
Start: 01/25/08 End: 06/21/10 Due: 06/21/11

Reslizumab to Prevent Post-treatment Eosinophilia in Loiasis

Phase: N/A Priority: Normal
NCT ID: NCT01111305 Org: User:
Start: 04/30/10 End: 09/30/17 Due: 09/30/18

An Open Label, Non-Comparative, Multicenter, Phase III Trial of the Efficacy, Safety and Toleration of Voriconazole in the Primary or Secondary Treatment of Invasive Fungal Infections

Phase: N/A Priority: Normal
NCT ID: NCT00001757 Org: User:
Start: 11/30/97 End: 07/31/00 Due: 07/31/01

Interleukin-7 (CYT107) Treatment of Idiopathic CD4 Lymphocytopenia: Expansion of CD4 T Cells (ICICLE)

Phase: N/A Priority: Normal
NCT ID: NCT00839436 Org: User:
Start: 02/28/09 End: 09/30/14 Due: 09/30/15

Early Versus Standard Start of Anti-HIV Therapy for Treatment-Naive Adults in Haiti

Phase: N/A Priority: Normal
NCT ID: NCT00120510 Org: User:
Start: 07/31/07 End: 09/30/09 Due: 09/30/10

Safety and Immunotherapeutic Activity of an Anti-PD-1 Antibody (Cemiplimab) in Participants With HIV-1 on Suppressive cART

Phase: N/A Priority: Normal
NCT ID: NCT03787095 Org: User:
Start: 08/13/19 End: 08/18/20 Due: 08/18/21

Evaluating the Safety, Pharmacokinetics, and Antiviral Activity of a Human Monoclonal Antibody (VRC01) in HIV-Infected Adults Undergoing a Brief Treatment Interruption

Phase: N/A Priority: Normal
NCT ID: NCT02463227 Org: User:
Start: 08/31/15 End: 10/31/16 Due: 10/31/17

Promoting Tolerance to Peanut in High-Risk Children

Phase: N/A Priority: Normal
NCT ID: NCT00329784 Org: User:
Start: 12/31/06 End: 05/31/14 Due: 05/31/15

Validation of System for Monitoring the Effectiveness of Antiretroviral Therapy in HIV-Infected Patients in Africa

Phase: N/A Priority: Normal
NCT ID: NCT00341393 Org: User:
Start: 02/16/06 End: 11/15/07 Due: 11/15/08

Immune Response to a Therapeutic HIV Vaccine Followed by Treatment Interruption in Patients With Acute or Recent HIV Infection

Phase: N/A Priority: Normal
NCT ID: NCT00183261 Org: User:
Start: 03/31/06 End: 10/31/10 Due: 10/31/11

Safety of and Immune System Response to an HIV Vaccine (EP HIV-1090) in HIV Uninfected Adults

Phase: N/A Priority: Normal
NCT ID: NCT00054860 Org: User:
Start: - End: 09/30/05 Due: 09/30/06

A Study to Demonstrate That Anti-HIV Drug Therapy Can be Stopped Without Causing Viral Resistance, and to Characterize Drug Elimination From the Body

Phase: N/A Priority: Normal
NCT ID: NCT00029341 Org: User:
Start: - End: - Due: -

Evaluating the Safety and Tolerability of Antiretroviral Drug Regimens Used as Pre-Exposure Prophylaxis to Prevent HIV Infection in At-Risk Men Who Have Sex With Men and in At-Risk Women

Phase: N/A Priority: Normal
NCT ID: NCT01505114 Org: User:
Start: 06/30/12 End: 11/30/15 Due: 11/30/16

Comparing the Safety, Effectiveness, and Tolerability of Three Anti-HIV Drug Regimens for Treatment-Naive Patients

Phase: N/A Priority: Normal
NCT ID: NCT00050895 Org: User:
Start: - End: 03/31/06 Due: 03/31/07